Brigatinib (Synonyms: 布格替尼; AP-26113)
目录号: PL02936 纯度: ≥99%
CAS No. :1197953-54-0
商品编号 规格 价格 会员价 是否有货 数量
PL02936-5mg 5mg ¥741.82 请登录
PL02936-10mg 10mg ¥1174.55 请登录
PL02936-50mg 50mg ¥3523.64 请登录
PL02936-100mg 100mg ¥5625.45 请登录
PL02936-200mg 200mg 询价 询价
PL02936-500mg 500mg 询价 询价
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Brigatinib
中文别名
布格替尼;5-氯-N2-[4-[4-(二甲基氨基)-1-哌啶基]-2-甲氧基苯基]-N4-[2-(二甲基亚膦酰)苯基]-2,4-嘧啶二胺
英文名称
Brigatinib
英文别名
Brigatinib;2-METHYL-3-FLUORO-PHENYLBORONIC ACID;Ap26113;5-Chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-2,4-pyrimidinediamine;Ap26113; brigatinib;Brigatinib [USAN];Brigatinib (AP26113);HYW8DB273J;Brigatinib (USAN);2,4-Pyrimidinediamine, 5-chloro-N4-(2-(dimethylphosphinyl)phenyl)-N2-(2-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)-;5-Chloro-N~4~-[2-(Dimethylphosphoryl)phenyl]-N~2~-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl)piperidin-1-Yl]phenyl}pyrimidine-2,4-Diamine;Brigatiib;Alunbrig (TN);2,4-Pyrimidinediamine, 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-pip
Cas No.
1197953-54-0
分子式
C29H39ClN7O2P
分子量
584.09
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
Brigatinib (AP-26113) 是有效,选择性的 ALK 抑制剂,IC50 值为 0.6 nM。
生物活性
Brigatinib (AP-26113) is a highly potent and selective ALK inhibitor, with an IC 50 of 0.6 nM.
性状
Solid
IC50 & Target[1][2]
IC50: 0.6 nM (ALK)
体外研究(In Vitro)
Brigatinib potently inhibits the in vitro kinase activity of ALK (IC50, 0.6 nM) and all five mutant variants tested, including G1202R (IC50, 0.6-6.6 nM). Brigatinib demonstrates a high degree of selectivity, only inhibiting 11 additional native or mutant kinases with IC50 <10 nM. These include ROS1, FLT3, and mutant variants of FLT3 (D835Y) and EGFR (L858R; IC50, 1.5-2.1 nM). Brigatinib exhibits more modest activity against EGFR with a T790M resistance mutation (L858R/T790M), native EGFR, IGF1R, and INSR (IC50, 29-160 nM) and does not inhibit MET (IC50 >1000 nM). In cellular assays, brigatinib inhibits ALK and ROS1 with IC50s of 14 and 18 nM, respectively. Brigatinib inhibits FLT3 and IGF-1R with about 11-fold lower potency (IC50, 148-158 nM) and inhibits mutant variants of FLT3 and E
体内研究(In Vivo)
Brigatinib (10, 25, or 50 mg/kg once daily, p.o.) leads to a dose-dependent inhibition of tumor growth in ALK Karpas-299 (ALCL) and H2228 (NSCLC) xenograft mouse models. Brigatinib markedly enhances survival of mice bearing ALK brain tumors compared with PF-02341066. Brigatinib (10, 25, 50 mg/kg, p.o.) results in dose-dependent antitumor activity, with tumor regressions in a mouse model of NSCLC. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Zhang S, et al. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res. 2016 Nov 15;22(22):5527-5538
[2]. Huang WS, et al. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. J Med Chem. 2016 May 26;59(10):4948-64.
溶解度数据
In Vitro: Ethanol : 10 mg/mL (17.12 mM; Need ultrasonic and warming)DMSO : 2 mg/mL (3.42 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2